###### Strengths and limitations of this study

-   A study design that made it possible to accumulate and present current evidence regarding clinical significance of the sole presence of autoantibodies for idiopathic pulmonary fibrosis, which was previously reported in a small study.

-   A difficulty in combining all of the results due to substantial heterogeneity between studies.

-   Inconclusive results due to a small number of studies and the scarcity of multivariate analyses.

Introduction {#s1}
============

Idiopathic pulmonary fibrosis (IPF) is chronic fibrosing interstitial pneumonia of unknown aetiology and the most common type among idiopathic interstitial pneumonias (IIPs).[@R1] IPF is characterised by pathological patterns of usual interstitial pneumonia (UIP) and diagnosed based on the exclusion of known causes such as connective tissue diseases (CTDs), drug toxicity and dust exposure.[@R2] However, it is often difficult to exclude all of these possible causes, in particular, underlying CTDs. This is because interstitial pneumonia can be the sole presenting manifestation[@R3] or CTDs may be unrecognised due to subtle clinical presentations.[@R4] In addition, all symptoms or signs suggestive of CTDs may not necessarily emerge at the same time.[@R5] As a result, some patients cannot be diagnosed as CTD-IP regardless of an implication of autoimmune features.[@R6] Historically, these cases were described using diverse nomenclatures such as undifferentiated CTD-associated IP,[@R7] lung-dominant CTD[@R8] and autoimmune-featured interstitial lung disease (ILD).[@R9] Recently, a new classification terminology, interstitial pneumonia with autoimmune features (IPAF), has been proposed for research purpose to focus on a more uniform group of patients who can be classified into this possibly distinct clinical entity.[@R10] This criteria consist of clinical, serological and morphologic domains. Although UIP is noted to be complicated by some systemic autoimmune disease such as rheumatoid arthritis (RA),[@R11] this pathological finding is not a part of classification criteria of IPAF as it is less specific to CTDs in contrast to non-specific interstitial pneumonia, which is reported to be the most common pathological change in CTD-IP.[@R12] As a result, IPF/UIP with the sole presence of autoantibodies does not meet the IPAF criteria and is still clinically diagnosed as IPF according to the current international guideline.[@R2] However, most of the previous reports regarding autoantibodies in patients with IPF were small studies in a single institution[@R13] and thus its clinical implications are still uncertain. Therefore, the aim of this systematic review and meta-analysis is to clarify prognostic significance of autoantibodies for IPF. The protocol of this study was registered with PROSPERO (International Prospective Register of Systematic Reviews).[@R14]

Methods {#s2}
=======

This review was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses[@R15] and the Meta-analysis of Observational Studies in Epidemiology statement.[@R16] The methods of the review were described briefly as the in-depths were previously reported as a protocol paper.[@R17]

Patient and public involvement {#s2a}
------------------------------

There was no patient and public involvement in the whole process of conducting this research.

Eligibility {#s2b}
-----------

This review included any type of primary studies aside from a case report where the effect of autoantibodies was comparatively investigated for the outcome of IPF. IPF was diagnosed based on previously published joint statement of American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association (ATS/ERS/JRS/ALAT).[@R2] If IPF was not mentioned, radiological and/or pathological UIP was also eligible if it was reported as idiopathic excluding possible secondary causes. There was no limitation of follow-up lengths and patients could be included at any point of time during their disease course.

Autoantibodies of interest in this study included both non-specific and specific antibodies against systemic self-antigens such as the ones listed in the serological domain of IPAF, which are closely related to CTDs.[@R10] Antineutrophil cytoplasmic antibody (ANCA) targeted against myeloperoxidase (MPO) or proteinase 3 (PR3) also constituted autoantibodies in this study since ANCA-associated vasculitides is reported to be complicated with pulmonary fibrosis, particularly UIP[@R18] although this autoantibody was not included in the IPAF classification criteria due to a different disease entity.[@R10] The measurement and the reference value of these laboratory tests were determined by each research institution.

Primary outcomes were all-cause and pulmonary-cause mortality. Secondary outcomes were a progression of the disease and a deterioration of health-related quality of life. The development of a defined autoimmune disease over the follow-up periods of time was also included in the secondary outcome.

Only English articles published in 2002 or later were eligible as current classification system of IIPs was established in that year.[@R1] Editorials, letters and review articles were all ineligible and conference proceedings were also excluded due to concerns of insufficient information.

Search of studies {#s2c}
-----------------

The following electronic databases, Medline (Ovid), EMBASE (Ovid) and Science Citation Index Expanded (Web of Science), were searched using subject headings and text words of study population such as 'idiopathic pulmonary fibrosis' and 'autoantibodies', which were modified depending on each database[@R19] and combined with the sensitive methodology filter for prognosis (from 1 January 2002 through 12 February 2019) (online [supplementary e-appendix](#SP1){ref-type="supplementary-material"}). Grey literature was sought to be identified through Google Scholar.[@R21] Reference lists of eligible studies and relevant review articles were also hand-searched to identify additional reports.
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Study selection and data collection {#s2d}
-----------------------------------

Two reviewers (HK and OMP) independently examined titles and abstracts of all retrieved articles after removing duplicates and selected eligible studies. Data were also extracted by the same reviewers based on the predefined data extraction form[@R17] and a disagreement through all these processes was sought to be resolved through discussion between the reviewers. Extracted data included the first author name, publication year, study location, study design, the number of participants and their demographic features, autoantibodies tested, outcomes, methods for statistical analysis, summary statistics and items associated with risk of bias.

Risk of bias in individual studies {#s2e}
----------------------------------

A risk of bias in individual studies was assessed by the Quality in Prognostic Studies tool.[@R22] It consisted of six domains, which was rated as either low, moderate or high and a study with low risk of bias in all domains was designated as a study with low risk of bias.

Statistical analysis {#s2f}
--------------------

Binary outcomes were to be summarised as the odds ratio (OR), risk ratio (RR) or hazard ratio (HR). If summary statistics were not obtained directly, they were estimated from available data such as the Kaplan-Meier survival curve and the log rank test[@R23] or calculated manually based on absolute numbers in two comparative groups. If the outcomes were continuous, the summary effect was to be presented as the mean difference or the difference of the median value.

The results were pooled if the effect of a certain autoantibody on a predefined outcome for patients with IPF was presented by the same summary statistics in three or more studies and otherwise they were reported qualitatively. Univariate results were sought to be combined whereas multivariate results were presented descriptively as the final model with adjusted factors would have been diverse between studies. Meta-analysis was conducted by a random-effects model with the DerSimonian and Laird method[@R24] using the statistical software, Review Manager (RevMan) V.5.3. The result was presented with the 95% confidence interval (CI) with statistical significance set at the 5% level and the 95% prediction interval (PI) was also calculated.[@R25] Heterogeneity was assessed by the Q statistics and the I^2^. Statistical significance of the test for heterogeneity was set at the 10% level and the magnitude was interpreted as not important (0%--30%), moderate (30%--50%), substantial (50%--70%) and considerable (70%--100%).[@R26] Subgroup analysis was to be conducted based on potential sources of heterogeneity such as the gender and study location (Asia vs non-Asia). Sensitivity analysis was also to be conducted focusing on studies with low risk of bias alone. Small study bias including publication bias was to be examined graphically by a funnel plot and statistically by Egger's test[@R27] if 10 or more studies were available. Statistical significance of the test was set at the 10% level.

Evaluating the presented evidence {#s2g}
---------------------------------

The Grades of Recommendation, Assessment, Development and Evaluation (GRADE) system was applied to evaluate the quality of evidence identified regarding clinical significance of autoantibodies for IPF.[@R28]

Results {#s3}
=======

Search strategy {#s3a}
---------------

A total of 4603 records were retrieved through a search of four electronic databases. After removing 365 duplicates, 1669 articles of ineligible types and 2520 reports of irrelevant subjects through screening titles and abstracts, the remaining 49 articles were retrieved as full-texts. Out of these reports, 40 failed to meet eligibility criteria and finally nine articles/studies were included in this review.[@R13] No additional reports were identified through a hand-search of references of eligible reports and relevant review articles ([figure 1](#F1){ref-type="fig"}).

![Study flow diagram. A total of 4603 records were retrieved through a search of Medline, EMBASE, Science Citation Index Expanded and Google Scholar. After removing 365 duplicates, 1669 reports were excluded due to ineligible types, which included 954 conference proceedings, 141 non-English articles, 423 case reports, 131 review articles and 20 letters. After excluding 2520 more reports due to irrelevant subjects through screening titles and abstracts, the remaining 49 articles were retrieved as full-texts. Out of these reports, 40 failed to meet eligibility criteria and finally nine articles/studies were included in this review. Meta-analysis was conducted for four studies. CTD, connective tissue disease; ILD, interstitial lung disease; IPAF, interstitial pneumonia with autoimmune features.](bmjopen-2018-027849f01){#F1}

Characteristics of included studies {#s3b}
-----------------------------------

All nine studies were of retrospective cohort design and included a total of 1950 participants. The majority of patients were men with smoking history, and the mean and median age was around 60s or 70s. Four studies[@R13] tested both non-specific autoantibodies such as antinuclear antibody (ANA) and rheumatoid factor (RF), and specific autoantibodies. One study[@R31] only examined ANA and RF, while the other four studies[@R33] only investigated MPO- and/or PR3-ANCA ([table 1](#T1){ref-type="table"}). The reference value for both ANA and RF was diverse between studies. ANA was identified in between 1% and 56.3% of patients depending on studies, while RF was positive in between 6% and 17.6% of patients. MPO-ANCA was tested in seven studies,[@R13] which demonstrated positivity as between 0% and 32.1%, while anticyclic citrullinated peptide (CCP) antibody was examined in three studies[@R13] which reported that it was positive in between 1.0% and 7.3%. All studies contained some risk of bias, in particular, study attrition was insufficiently explained in all studies. For confounding factors and statistical analysis, all studies except one had a high risk of bias and one had a medium risk of bias ([table 2](#T2){ref-type="table"}).

###### 

Characteristics of included studies\*

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Studies             Country   Study design           Patient (n) (male/female)   Age (years)               Smoking history (positivity) (n (%))   Follow-up length           Autoantibodies (positivity)\     Outcomes
                                                                                                                                                                               (n (% of tested))†               
  ------------------- --------- ---------------------- --------------------------- ------------------------- -------------------------------------- -------------------------- -------------------------------- ----------------------------
  Kang *et al*\       Korea     Retrospective cohort   526 (--)                    --                        --                                     --                         ANA (≥1:40) (157 (31.5%))\       CTD development\
  (2013)[@R29]                                                                                                                                                                 RF (≥20 IU/mL) (58 (11.9%))\     All-cause mortality
                                                                                                                                                                               MPO-ANCA (27 (6.6%))\            
                                                                                                                                                                               PR3-ANCA (9 (2.2%))\             
                                                                                                                                                                               Anti-CCP antibody (10 (7.3%))\   
                                                                                                                                                                               Others‡                          

  Lee *et al*\        USA       Retrospective cohort   67 (51/16)                  Mean (±SD)\               50 (74.5)                              Median (IQR) (days)\       ANA (≥1:320) (1 (1%))\           All-cause mortality
  (2013)[@R13]                                                                     69±8                                                             754 (323--1143)/\          RF (≥60 IU/mL) (4 (6%))\         
                                                                                                                                                    1033 (269--1316)           MPO-ANCA (0 (0%))\               
                                                                                                                                                                               PR3-ANCA (1 (1%))\               
                                                                                                                                                                               Anti-CCP antibody (1 (1%))\      
                                                                                                                                                                               Others§                          

  Moua *et al*\       USA       Retrospective cohort   389 (241/148)               Mean (±SD) 63.3±10.47/\   70 (62.5)/178 (64.3)                   Median (months)\           ANA (≥1:80) (65 (16.8%))\        All-cause mortality
  (2014)[@R30]                                                                     64.6±9.17                                                        43.5                       RF (≥15 IU/mL) (51 (17.6%))\     
                                                                                                                                                                               Anti-CCP antibody (1 (1.0%))\    
                                                                                                                                                                               Others¶                          

  Song *et al*\       Korea     Retrospective cohort   61 (46/15)                  Mean (±SD) 59.2±8.3       42 (68.9)                              Median (range) (months)\   ANA (19 (31.1%))\                All-cause mortality
  (2009)[@R31]                                                                                                                                      22.0 (1.9--138.5)          RF (8 (13.1%))                   

  Kagiyama *et al*\   Japan     Retrospective cohort   504 (376/128)               Mean (±SD) 69.5±8.1       24 (66.7)/359 (76.7)                   Median (IQR) (years)\      ANA (284 (56.3%))\               All-cause mortality\
  (2015)[@R32]                                                                                                                                      3.95 (1.84--6.64)          RF (84 (16.7%))\                 MPA development\*\*
                                                                                                                                                                               MPO-ANCA (20 (4.0%))\            
                                                                                                                                                                               PR3-ANCA (16 (3.2%))             

  Hosoda *et al*\     Japan     Retrospective cohort   120 (90/30)                 Median (range)\           86 (71.7)                              Median (range) (months)\   MPO-ANCA (12 (10.0%))            All-cause mortality\
  (2016)[@R33]                                                                     65.2 (48--74)/\                                                  72 (14--195)/\                                              MPA development
                                                                                   65.6 (37--78)                                                    56 (4--168)                                                 

  Nozu *et al*\       Japan     Retrospective cohort   53 (25/28)                  Median (range)\           -- (55.9)                              Range (months)\            MPO-ANCA (17 (32.1%))\           All-cause mortality\
  (2009)[@R34]                                                                     69 (52--80)/\                                                    1--90/1--58                PR3-ANCA (2 (3.8%))              MPA development\
                                                                                   72 (48--86)                                                                                                                  Radiological improvement

  Hozumi *et al*\     Japan     Retrospective cohort   97 (86/11)                  Median (range)\           3 (100.0)/77 (81.9)                    Median (range) (years)\    MPO-ANCA (0 (0%))\               All-cause mortality\
  (2016)[@R35]                                                                     79 (70--79)/\                                                    1.33 (0.92--3.1)/\         PR3-ANCA (3 (3.1%))              Pulmonary-cause mortality
                                                                                   70 (51--85)                                                      3.0 (0.36--10.6)                                            

  Hozumi *et al*\     Japan     Retrospective cohort   133 (114/19)                Median (IQR)\             13 (86.7)/95 (80.5)                    Median (IQR) (years)\      MPO-ANCA (15 (11.3%))            All-cause mortality\
  (2018)[@R36]                                                                     68 (61--77)/\                                                    5.9 (3.9--12.6)/\                                           Pulmonary-cause mortality\
                                                                                   71 (64--76)                                                      3.4 (1.7--4.8)                                              MPA development
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Comparative numbers in each cell indicating data of IPF with vs without autoantibodies unless otherwise specified while a single number indicating data derived from the whole group of patients.

†Specifying only ANA, RF, ANCA and anti-CCP antibody if tested since these autoantibodies are most frequently examined for screening CTDs or closely related to UIP pattern, while 'others' including only autoantibodies that showed positive results.

‡Including anti-Jo-1 antibody (4 (1.0%)), anti-SS-A antibody (10 (2.3%)), anti-Scl-70 antibody (3 (0.7%)), anti-RNP antibody (1 (0.5%)) and anti-Sm antibody (1 (0.5%)) (number of positivity (% of tested)).

§Including antichromatin antibody (1 (1%)), anti-ds DNA antibody (1 (1%)), anti-RNP antibody (4 (6%)), anti-Scl-70 antibody (2 (3%)) and anti-SS-A antibody (3 (4%)) (number of positivity (% of tested)).

¶Including ENA (5 (2.5%)), anti-SS-A antibody (8 (7.9%)), anti-SS-B antibody (2 (2.0%)), antialdolase antibody (7 (17.9%)), anti-ds DNA antibody (2 (3.3%)), antihistone antibody (2 (25%)) and anti-mitochondria antibody (1 (6.7%)) (number of positivity (% of tested)).

\*\*n=488.

ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; CCP, cyclic citrullinated peptide; CTD, connective tissue disease; ds DNA, double-stranded DNA; ENA, extractable nuclear antigen; IPF, idiopathic pulmonary fibrosis; MPA, microscopic polyangiitis; MPO, myeloperoxidase; PR3, proteinase 3; RF, rheumatoid factor, RNP, ribonucleoprotein; UIP, usual interstitial pneumonia.

###### 

Risk of bias in included studies assessed by the Quality in Prognostic Studies tool\*

  Studies                         Study participation   Study attrition   Prognostic factor measurement   Outcome measurement   Study confounding   Statistical analysis and reporting
  ------------------------------- --------------------- ----------------- ------------------------------- --------------------- ------------------- ------------------------------------
  Kang *et al* (2013)[@R29]       Medium risk           **High risk**     Medium risk                     Low risk              **High risk**       **High risk**
  Lee *et al* (2013)[@R13]        Medium risk           **High risk**     Low risk                        Low risk              **High risk**       Medium risk
  Moua *et al* (2014)[@R30]       Low risk              **High risk**     Medium risk                     Low risk              Low risk            **High risk**
  Song *et al* (2009)[@R31]       **High risk**         **High risk**     **High risk**                   Low risk              **High risk**       **High risk**
  Kagiyama *et al* (2015)[@R32]   Medium risk           **High risk**     Low risk                        Low risk              **High risk**       **High risk**
  Hosoda *et al* (2016)[@R33]     Low risk              **High risk**     Low risk                        Low risk              Medium risk         **High risk**
  Nozu *et al* (2009)[@R34]       **High risk**         **High risk**     Low risk                        Low risk              Medium risk         **High risk**
  Hozumi *et al* (2016)[@R35]     Medium risk           **High risk**     Low risk                        Low risk              Medium risk         **High risk**
  Hozumi *et al* (2018)[@R36]     **High risk**         **High risk**     Medium risk                     Low risk              Medium risk         **High risk**

\*Text in bold referring to high risk of bias.

Univariate analysis {#s3c}
-------------------

### All-cause mortality {#s3c1}

Among diverse autoantibodies tested, the effect of ANA and RF on all-cause mortality was reported separately in two studies. Kang *et al* [@R29] demonstrated no significant difference of the median survival time (MST) between IPF with and without ANA (40.6 vs 46.2 months). Kagiyama *et al* [@R32] also reported non-significant result for ANA with HR of 1.31 (95% CI: 0.98 to 1.76). Kang *et al* [@R29] demonstrated no significant difference of the MST between IPF with and without RF (44.5 vs 48.8 months). Kagiyama *et al* [@R32] also reported non-significant result for RF with HR of 1.16 (95%CI: 0.83 to 1.61) ([table 3](#T3){ref-type="table"}).

###### 

Summary of the effect of autoantibodies for idiopathic pulmonary fibrosis\*

  ---------------------------------------------------------------------------------------------------------------------------------
  Outcomes/autoantibodies combination   Studies                         Univariate (95% CI)            Multivariate (95% CI)
  ------------------------------------- ------------------------------- ------------------------------ ----------------------------
  All-cause mortality                                                                                  

   ANA (≥1:40)                          Kang *et al* (2013)[@R29]       Median survival time\          --
                                                                        40.6 vs 46.2 months (p=0.72)   

   (Reference value not specified)      Kagiyama *et al* (2015)[@R32]   HR 1.31 (0.98 to 1.76)         --

   RF (≥20 IU/mL)                       Kang *et al* (2013)[@R29]       Median survival time\          --
                                                                        44.5 vs 48.8 months (p=0.43)   

   (Reference value not specified)      Kagiyama *et al* (2015)[@R32]   HR 1.16 (0.83 to 1.61)         --

   MPO-ANCA                             Kagiyama *et al* (2015)[@R32]   HR 1.65 (0.97 to 2.80)         HR 1.48 (0.84 to 2.62)

  Hosoda *et al* (2016)[@R33]           HR 0.58 (0.25 to 1.38)          --                             

  Hozumi *et al* (2018)[@R36]           **HR 2.69 (1.27 to 5.70)**      --                             

   PR3-ANCA                             Kagiyama *et al* (2015)[@R32]   **HR 2.99 (1.52 to 5.86)**     **HR 2.42 (1.23 to 4.76)**

  Hozumi *et al* (2016)[@R35]           RR 1.79 (0.77 to 4.16)          --                             

   ANCA                                 Nozu *et al* (2009)[@R34]       HR 0.60 (0.23 to 1.57)         --

  Pulmonary-cause mortality                                                                            

   MPO-ANCA                             Hozumi *et al* (2018)[@R36]     RR 1.23 (0.74 to 2.07)         --

   PR3-ANCA                             Hozumi *et al* (2016)[@R35]     RR 2.24 (0.95 to 5.28)         --

  CTD incidence                                                                                        

   ANA (≥1:40)                          Kang *et al* (2013)[@R29]       **RR 7.11 (p=0.001)**          --

   RF (≥20 IU/mL)                       Kang *et al* (2013)[@R29]       RR 2.26 (p=0.19)               --

  MPA incidence                                                                                        

   MPO-ANCA                             Kagiyama *et al* (2015)[@R32]   **RR 11.7 (3.15 to 43.5)**     --

  Hosoda *et al* (2016)[@R33]           **RR 61.0 (3.35 to 1108.5)**    --                             

  Nozu *et al* (2009)[@R34]             **RR 17.8 (1.02 to 311.6)**     --                             

  Hozumi *et al* (2018)[@R36]           **RR 99.4 (5.88 to 1679.7)**    --                             

  Radiological improvement                                                                             

   ANCA                                 Nozu *et al* (2009)[@R34]       RR 1.53 (0.99 to 2.36)         --
  ---------------------------------------------------------------------------------------------------------------------------------

\*Text in bold referring to a significant result and comparative numbers indicating data of IPF with vs without autoantibodies.

ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; CCP, cyclic citrullinated peptide; CI, confidence interval; CTD, connective tissue disease; IPF, idiopathic pulmonary fibrosis; MPA, microscopic polyangiitis; MPO, myeloperoxidase; PR3, proteinase 3; RF, rheumatoid factor; RR, risk ratio.

The effect of MPO-ANCA on all-cause mortality was reported in three studies. One of these studies demonstrated a significant result with HR of 2.69 (95% CI: 1.27 to 5.70) (eight deaths in 15 patients with MPO-ANCA),[@R36] whereas the results were non-significant and inconsistent in the others with HRs of 1.65 (95% CI: 0.97 to 2.80)[@R32] and 0.58 (95% CI: 0.25 to 1.38) (five deaths in 12 patients with MPO-ANCA),[@R33] respectively. The effect of PR3-ANCA on all-cause mortality was reported in two studies.[@R32] [@R35] The former study demonstrated a significant result with HR of 2.99 (95% CI: 1.52 to 5.86) and the latter study also reported the same trend with RR of 1.79 (95% CI: 0.77 to 4.16) (two deaths in three patients with PR3-ANCA) although it was not statistically significant. ANCA was not significantly associated with all-cause mortality with HR of 0.60 (95% CI: 0.23 to 1.57) (six deaths in 19 patients with ANCA) in one study.[@R34] As approximately 90% of ANCA were composed of MPO-ANCA in Nozu *et al*,[@R34] the result of the study was combined with those of the other three studies that reported MPO-ANCA.[@R32] [@R33] [@R36] Meta-analysis of these four studies demonstrated that MPO-ANCA was not significantly associated with all-cause mortality with HR of 1.19 (95% CI: 0.60 to 2.36/95% PI: 0.06 to 22.2) although there was considerable heterogeneity between studies ([figure 2](#F2){ref-type="fig"}).

![Forest plot of the result of univariate analysis of myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA) for all-cause mortality. The univariate results of MPO-ANCA for all-cause mortality in four studies were pooled and a total of 810 patients were included. MPO-ANCA was not significantly associated with all-cause mortality with HR of 1.19 (95% CI: 0.60 to 2.36, p=0.63). The 95% prediction interval was between 0.06 and 22.2. There was considerable heterogeneity (Χ^2^=10.29, p=0.02, I^2^=71%).](bmjopen-2018-027849f02){#F2}

Three studies,[@R13] [@R30] [@R31] which reported the effect of the presence of any autoantibody together instead of focusing on a single autoantibody, were excluded from further analysis since such data handling is impractical as it ignores clinical relevance of each autoantibody.

Autoimmune disease incidence {#s3d}
----------------------------

The development of CTDs was reported in only one study,[@R29] which was demonstrated to be 2.5% of a total of 526 patients. It stated that the most frequently identified CTD was RA (61.5%), which was followed by Sjögren syndrome (23.1%). There was a significant association between the presence of ANA (≥1:40) and CTD incidence with RR of 7.11 (p=0.001) (10 cases in 157 patients with ANA), whereas RF (≥20 IU/mL) was not significantly associated with CTD incidence with RR of 2.26 (p=0.19) (three cases in 58 patients with RF) ([table 3](#T3){ref-type="table"}). The development of microscopic polyangiitis (MPA) was reported in four studies[@R32] ([table 3](#T3){ref-type="table"}). The incidence of MPA cases was 3, 3, 4 and 6 in 20, 12, 19 and 15 patients with MPO-ANCA in respective studies. Meta-analysis of the results demonstrated higher incidence of MPA with the presence of MPO-ANCA with RR of 20.2 (95% CI: 7.22 to 56.4/95% PI: 2.11 to 192.8) ([figure 3](#F3){ref-type="fig"}).

![Forest plot of the result of univariate analysis of myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA) for the development of microscopic polyangiitis (MPA). The univariate results of MPO-ANCA for the development of MPA in four studies were pooled and a total of 794 patients were included. MPO-ANCA was significantly associated with the development of MPA with risk ratio (RR) of 20.2 (95% CI: 7.22 to 56.4, p\<0.00001). The 95% prediction interval was between 2.11 and 192.8. There was no heterogeneity (Χ^2^=2.45, p=0.48, I^2^=0%).](bmjopen-2018-027849f03){#F3}

Other outcomes {#s3e}
--------------

Pulmonary-cause mortality for MPO-ANCA and PR3-ANCA was reported in one study each. Hozumi *et al* [@R36] and Hozumi *et al* [@R35] demonstrated non-significant results with RRs of 1.23 (95% CI: 0.74 to 2.07) (eight cases in 15 patients with MPO-ANCA) and 2.24 (95% CI: 0.95 to 5.28) (two cases in three patients with PR3-ANCA), respectively ([table 3](#T3){ref-type="table"}). Radiological improvement after the corticosteroid and cyclophosphamide therapy was compared between ANCA-positive and negative groups in one study,[@R34] which demonstrated non-significant result with RR of 1.53 (95%CI: 0.99 to 2.36) ([table 3](#T3){ref-type="table"}).

### Multivariate analysis {#s3e1}

The effect of MPO-ANCA and PR3-ANCA on all-cause mortality was reported using multivariate models in only one study.[@R32] MPO-ANCA was not significantly associated with all-cause mortality with HR of 1.48 (95% CI: 0.84 to 2.62), whereas there was a significant association of PR3-ANCA with all-cause mortality with HR of 2.42 (95% CI: 1.23 to 4.76) ([table 3](#T3){ref-type="table"}).

### Additional analysis {#s3e2}

Neither subgroup analysis nor sensitivity analysis was conducted due to a small number of studies and some risk of bias identified in all studies. Small study bias was unable to be examined due to a small number of studies.

### Quality of evidence {#s3e3}

The GRADE system rated the quality of evidence as either low or very low for all of the autoantibodies for IPF ([table 4](#T4){ref-type="table"}).

###### 

Assessment of quality of evidence of autoantibodies for idiopathic pulmonary fibrosis by the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) system

  Outcomes                    Autoantibodies   Analysis\*   GRADE factors                                              
  --------------------------- ---------------- ------------ --------------- ----- ----- ---- ---- ---- ---- ---------- ----------
  All-cause mortality         ANA              Uni          1               \+    −     −    \+   −    −    −          Very low
                              Multi            No data                                                                 
  RF                          Uni              1            \+              −     −     \+   −    −    −    Very low   
                              Multi            No data                                                                 
  MPO-ANCA                    Uni              1            \+              \+    −     \+   −    −    −    Very low   
                              Multi            1            \+              N/A   −     \+   −    −    −    Very low   
  PR3-ANCA                    Uni              1            \+              −     −     \+   −    −    −    Very low   
                              Multi            1            \+              N/A   −     \+   −    −    −    Very low   
  ANCA                        Uni              1            \+              N/A   −     \+   \+   −    −    Very low   
                              Multi            No data                                                                 
  Pulmonary-cause mortality   MPO-ANCA         Uni          1               \+    N/A   −    \+   \+   −    −          Very low
                              Multi            No data                                                                 
  PR3-ANCA                    Uni              1            \+              N/A   −     \+   \+   −    −    Very low   
                              Multi            No data                                                                 
  CTD incidence               ANA              Uni          1               \+    N/A   −    \+   −    \+   −          Low
                              Multi            No data                                                                 
  RF                          Uni              1            \+              N/A   −     \+   −    \+   −    Low        
                              Multi            No data                                                                 
  MPA incidence               MPO-ANCA         Uni          1               \+    −     −    \+   −    \+              Low
                              Multi            No data                                                                 
  Radiological improvement    ANCA             Uni          1               \+    N/A   −    \+   \+   −    −          Very low
                              Multi            No data                                                                 

\*'Uni' indicating univariate analysis, while 'multi' indicating multivariate analysis.

†N/A indicating not applicable due to only one study available.

ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; CTD, connective tissue disease; MPA, microscopic polyangiitis; MPO, myeloperoxidase; PR3, proteinase 3; RF, rheumatoid factor.

Discussion {#s4}
==========

This systematic review demonstrated that ANA was the most frequently identified autoantibody for patients with IPF. Based on the result of individual studies, MPO-ANCA and ANA were associated with the development of some autoimmune diseases. However, all-cause mortality was the same regardless of the presence of autoantibodies although MPO-ANCA and PR3-ANCA were demonstrated to be associated with worse prognosis in one study each. Based on the result of pooled data, the presence of MPO-ANCA was significantly associated with the development of MPA although there was no significant difference of all-cause mortality between IPF with and without this autoantibody.

Clinical significance of the sole presence of autoantibodies in IPF has yet to be elucidated. However, it may be related to the pathogenesis of IPF as autoimmunity has been reported to be involved in the development of IPF.[@R37] It was demonstrated that CD4 T cells would be activated by some autoantigen inside the lung and help B cells proliferate and produce autoantibodies.[@R39] Fibrosis and inflammation will be facilitated by a variety of molecules secreted during this entire process and the development of IPF may ensue.[@R39] Based on this explanation regarding the development of the disease, the presence of autoantibodies in IPF may be reflecting the underlying autoimmunity involved in its pathogenesis rather than suggesting a complication of autoimmune disease.[@R40] Another explanation for the presence of autoantibodies in IPF is a chance phenomenon as autoantibodies are noted to be detected in healthy people without any symptoms or signs suggestive of autoimmune disease.[@R41] These findings may suggest that autoantibodies in IPF would add no clinical significance and this argument seems to be more likely in a case of non-specific autoantibodies such as ANA and RF. Indeed, the positivity of RF was between 6% and 18% in this study, which is within the normal range for healthy population.[@R42] A high positive rate of ANA confirmed in this review may also be explained by the fact that all included studies were composed of elderly patients because it is reported that ANA positivity rises as the age increases.[@R41] However, the interpretation of non-specific autoantibodies in IPF will be changed depending on their titres. If the titre is high, it may still imply clinical relevance beyond a chance.[@R43] On the other hand, specific autoantibodies such as ANCA and anti-CCP antibody are closely related to a defined autoimmune disease as they directly involve the pathogenesis of the disease.[@R44] As a result, the presence of specific autoantibodies is likely to predict future development of autoimmune disease.[@R43] Although ANA (≥1:40) was demonstrated to be significantly associated with a higher incidence of CTDs in one study in this review, this relationship may have been confounded by the presence of anti-CCP antibody since this autoantibody was identified in 7.3% of patients and the majority of CTD cases that developed during follow-up periods were RA (61.5%). Furthermore, pooled data in this review also demonstrated that MPO-ANCA was significantly associated with the development of MPA. These findings are consistent with previous reports that the majority of UIP preceding CTD cases were manifested as RA and MPA over time.[@R46] As ANA is noted to be a less sensitive and specific marker for both of these diseases,[@R43] serological testing such as anti-CCP antibody and MPO-ANCA needs to be implemented to avoid a misdiagnosis of IPF and not to miss the chance of a proper treatment.

Although some autoantibodies in IPF were demonstrated to be predictive of future occurrence of autoimmune disease in this review, all autoantibodies aside from PR3-ANCA were not associated with all-cause mortality. There was also no significant difference of all-cause mortality between IPF with and without MPO-ANCA based on pooled data although there was considerable heterogeneity of the effect between studies. The prognosis of ILD is reported to be closely related to both radiological and pathological patterns and its underlying causes.[@R47] Previous studies mentioned that CTD/UIP usually demonstrates better survival than IPF/UIP,[@R50] while the prognosis of RA/UIP and MPA/UIP would be similar to that of IPF/UIP.[@R11] Based on these previous reports, the prognosis of IPF with autoantibodies may be different depending on the rate of autoimmune disease incidence and the proportion of underlying RA and MPA cases. In short, if autoantibodies in IPF are all non-specific with low titres, the prognosis may be similar to IPF without autoantibodies as they are likely to confer little additional clinical significance. However, if autoantibodies in IPF are specific or shown positive with high titres even if they are non-specific, the prognosis may depend on possible underlying autoimmune diseases. In the latter case, if IPF with autoantibodies includes a large number of cases that will evolve into RA or MPA, its prognosis may be the same as IPF without autoantibodies, which may be the case demonstrated in this review. Clinical significance of PR3-ANCA in IPF has yet to be elucidated. However, worse prognosis with this autoantibody in this review may be related to a missed diagnosis because it is fairly specific for granulomatosis with polyangiitis, a life-threatening systemic vasculitis.[@R52] Another potential factor that can influence clinical course of the disease is treatment. As IPF with autoantibodies is diagnosed as IPF under current diagnostic criteria,[@R2] therapeutic agents such as corticosteroids and immunosuppressive drugs may be reserved until it is revealed as a defined autoimmune disease. However, this clinical decision may deprive the chance of improving clinical course of the disease. In particular, IPF with MPO-ANCA may be complicated with acute respiratory failure due to diffuse alveolar haemorrhage caused by capillaritis, which is a critical condition and difficult to be treated.[@R53] An early intervention for IPF with MPO-ANCA may possibly prevent this fatal complication and improve the prognosis of the disease although further research is imperative to confirm this hypothesis.

There are some methodological limitations in this research. First, all studies included in this review were demonstrated to contain high risk of bias in at least one domain. In particular, the study attrition was not explained clearly in all studies and study confounders and statistical analysis were also uncertain. Second, relevant autoantibodies were not necessarily tested for all patients as all included studies were of retrospective design. Accordingly, there is a possibility of selection bias of patients and diagnostic misclassification between IPF with and without autoantibodies. Third, there was substantial clinical and methodological heterogeneity between studies. An example includes diverse positivity of autoantibodies such as ANA, which may have been caused by a different cohort, different methods of testing or different cut-off values. Fourth, due to heterogeneity and a small number of included studies, meta-analysis was only possible for two different outcomes for one autoantibody. As a consequence, most of the findings obtained in this review may possibly have been affected by type 2 error in an individual study. Finally, it was difficult to draw a definitive conclusion due to the scarcity of multivariate data.

Although these potential shortcomings may prevent an immediate application of the findings of this review into daily clinical practice, this study remains meaningful in that it clarified current evidence regarding clinical significance of autoantibodies for IPF. Further research of high-quality incorporating multivariate analysis is imperative to confirm the results of this review and to address other relevant autoantibodies and outcomes that have not been clarified in this research.

Conclusion {#s5}
==========

The presence of autoantibodies such as MPO-ANCA and ANA was demonstrated to be associated with the development of some autoimmune diseases for patients with IPF although there was no difference of all-cause mortality. However, the results should be interpreted with caution due to low evidence level.
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